Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Influenza · 3 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Influenza vaccine (A/H3N2, A/H1N1, and B strains) | BIOLOGICAL | - |
| Fluarix | BIOLOGICAL | - |
| Influenza | BIOLOGICAL | - |
| Influenza vaccine | BIOLOGICAL | - |
Inclusion Criteria: * Male or female adults (≥18 yrs) * Stable health status * Provide informed consent * Access to direct phone service (NOT a pay phone or a common-use phone service) * Eligible females must have a negative pregnancy test Exclusion Criteria: * Febrile illness (\>38.0°C oral temp...
Influenza vaccine is used for the prevention of influenza, commonly known as the flu. It is an investigational vaccine being developed by GSK plc (GSK) for use in adults aged 18 years and older. The vaccine is intended to stimulate the immune system to protect against influenza infection.
The Influenza vaccine is developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. GSK is conducting clinical trials to evaluate the vaccine's safety and immunogenicity in adult populations.
The Influenza vaccine is in Phase 3 clinical development. It is an investigational vaccine, meaning it has not yet been approved by regulatory authorities. Phase 3 trials are designed to confirm its efficacy and monitor adverse reactions in larger populations.
The Influenza vaccine has been studied in three completed Phase 3 clinical trials. These include NCT00197223, a post-marketing study in Czechia with 6,213 participants; NCT00197288, a comparison of immune responses in the United States with 1,847 participants; and NCT00380211, a safety and immunogenicity study in the United States with 660 participants.
The Influenza vaccine is compared against Fluarix and Fluzone in clinical trials. In NCT00197288, the immune response of the Influenza vaccine was compared with Fluarix and Fluzone. In NCT00380211, the safety and immunogenicity of FluLaval TR and Fluarix were evaluated. These are separate vaccines used as comparators.
The Influenza vaccine is a monoclonal antibody modality, designed to target influenza. It works by providing passive immunity through antibodies that neutralize the influenza virus, potentially offering protection against infection. The vaccine is administered to healthy adults to stimulate an immune response.